SynthesisBMC infectious diseases2020
Productivity costs from a dengue episode in Asia: a systematic literature review.
Synthesis in BMC infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Economic Impact of Dengue Virus in Mexico Over One Decade: A Systematic Literature Review (2010-2020).The International journal of health planning and management · 2026Pooled it
- The economic burden of dengue: a systematic literature review of unit costs for non-fatal episodes treated in the formal healthcare system.BMC infectious diseases · 2026Pooled it
- Epidemiology and costs of dengue in Thailand: A systematic literature review.PLoS neglected tropical diseases · 2022Pooled it
- Making scents of mosquito lures: semiochemical attractants for adult mosquitoes.Parasites & vectors · 2026Review
- The cost of dengue shock and septic shock in Vietnam: a patient-centred economic analysis.International health · 2026Observational
- Evaluating the economic burden of dengue in Sri Lanka: A systematic review of costs from 2010 to 2024.IJID regions · 2026Review
- Article
- An Introduction to Costing and the Types of Costs Used within Health Economic Studies.PharmacoEconomics - open · 2025Review
- GeneDrive.jl: A decision tool to optimize biological vector control strategies under climate change.PLoS computational biology · 2025Article
- Immune profiling in subclinical secondary dengue-infected cases reveals adaptive immune signatures correlated to protection from severe dengue.Cell host & microbe · 2025Article
- Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003: A modeling case study in Thailand.PLoS medicine · 2025Article
- Estimating per-infection cost and burden for dengue and Zika as a function of antibody-dependent enhancement.PLoS neglected tropical diseases · 2025Article
- Dengue Vaccination: A Practical Guide for Clinicians.Vaccines · 2025Review
- Epidemiological and cluster characteristics of dengue fever in Yunnan Province, Southwestern China, 2013-2023.BMC infectious diseases · 2025Article
- Addressing knowledge, attitude and practice gaps for effective dengue management strategies in Indonesia.Frontiers in public health · 2025Article
- Article
- Animal Models, Therapeutics, and Vaccine Approaches to Emerging and Re-Emerging Flaviviruses.Viruses · 2024Review
- Transfusion of Blood Products and Clinical Outcomes for Patients With Dengue Fever: A Systematic Review and Meta-analysis.Open forum infectious diseases · 2024Review
- The macroeconomic impact of a dengue outbreak: Case studies from Thailand and Brazil.PLoS neglected tropical diseases · 2024Article
- An overview of the perspectives used in health economic evaluations.Cost effectiveness and resource allocation : C/E · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDengue is a mosquito-borne viral infection which has been estimated to cause a global economic burden of US$8.9 billion per year. 40% of this estimate was due to what are known as productivity costs (the costs associated with productivity loss from both paid and unpaid work that results from illness, treatment or premature death). Although productivity costs account for a significant proportion of the estimated economic burden of dengue, the methods used to calculate them are often very variable within health economic studies. The aim of this review was to systematically examine the current estimates of the productivity costs associated with dengue episodes in Asia and to increase awareness surrounding how productivity costs are estimated.
methodWe searched PubMed and Web of Knowledge without date and language restrictions using terms related to dengue and cost and economics burden. The titles and abstracts of publications related to Asia were screened to identify relevant studies. The reported productivity losses and costs of non-fatal and fatal dengue episodes were then described and compared. Costs were adjusted for inflation to 2017 prices.
resultsWe reviewed 33 relevant articles, of which 20 studies reported the productivity losses, and 31 studies reported productivity costs. The productivity costs varied between US$6.7-1445.9 and US$3.8-1332 for hospitalized and outpatient non-fatal episodes, respectively. The productivity cost associated with fatal dengue episodes varied between US$12,035-1,453,237. A large degree of this variation was due to the range of different countries being investigated and their corresponding economic status. However, estimates for a given country still showed notable variation.
conclusionWe found that the estimated productivity costs associated with dengue episodes in Asia are notable. However, owing to the significant variation in methodology and approaches applied, the reported productivity costs of dengue episodes were often not directly comparable across studies. More consistent and transparent methodology regarding the estimation of productivity costs would help the estimates of the economic burden of dengue be more accurate and comparable across studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.